MYRIAD GENETICS, INC. (MYGN) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
50/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinMYGN / S&P 26.89% / 15.20% |
LoseMYGN / S&P -3.16% / 15.00% |
LoseMYGN / S&P -72.43% / 50.40% |
| 2026-Q11/3 |
LoseMYGN / S&P -26.83% / -4.33% |
LoseMYGN / S&P -0.28% / 11.30% |
WinMYGN / S&P 283.04% / 27.70% |
| 2025-Q41/3 |
LoseMYGN / S&P -14.94% / 2.65% |
LoseMYGN / S&P -1.56% / 9.00% |
WinMYGN / S&P 178.72% / 13.40% |
| 2025-Q32/3 |
WinMYGN / S&P 36.16% / 8.12% |
LoseMYGN / S&P 0.21% / 4.61% |
WinMYGN / S&P 238.28% / 13.45% |
| 2025-Q21/3 |
LoseMYGN / S&P -40.14% / 10.94% |
LoseMYGN / S&P 3.83% / 4.83% |
WinMYGN / S&P 139.11% / 10.63% |
| 2025-Q11/3 |
LoseMYGN / S&P -35.30% / -4.27% |
WinMYGN / S&P 7.38% / 4.98% |
LoseMYGN / S&P -60.00% / 10.57% |
| 2024-Q41/3 |
LoseMYGN / S&P -49.95% / 2.41% |
WinMYGN / S&P 11.21% / 5.25% |
LoseMYGN / S&P -55.66% / 6.15% |
| 2024-Q32/3 |
WinMYGN / S&P 11.98% / 5.89% |
WinMYGN / S&P 12.15% / 5.89% |
LoseMYGN / S&P -61.90% / 6.11% |
| 2024-Q22/3 |
WinMYGN / S&P 14.73% / 4.28% |
WinMYGN / S&P 14.78% / 5.38% |
LoseMYGN / S&P -41.12% / 5.12% |
| 2024-Q13/3 |
WinMYGN / S&P 11.39% / 10.56% |
WinMYGN / S&P 11.44% / 5.71% |
WinMYGN / S&P 55.56% / 5.59% |
| 2023-Q43/3 |
WinMYGN / S&P 19.33% / 11.69% |
WinMYGN / S&P 11.03% / 6.81% |
WinMYGN / S&P 128.78% / 7.78% |
| 2023-Q32/3 |
LoseMYGN / S&P -30.80% / -3.27% |
WinMYGN / S&P 11.04% / 7.52% |
WinMYGN / S&P 246.39% / -5.03% |
| 2023-Q21/3 |
LoseMYGN / S&P -0.22% / 8.74% |
LoseMYGN / S&P 3.96% / 9.50% |
WinMYGN / S&P 1166.67% / -8.57% |
| 2023-Q12/3 |
WinMYGN / S&P 60.10% / 7.50% |
LoseMYGN / S&P 1.80% / 10.77% |
WinMYGN / S&P 1400.00% / -15.69% |
| 2022-Q41/3 |
LoseMYGN / S&P -23.95% / 7.56% |
LoseMYGN / S&P -1.77% / 11.88% |
WinMYGN / S&P 265.79% / -17.99% |
| 2022-Q32/3 |
WinMYGN / S&P 5.01% / -4.88% |
LoseMYGN / S&P -3.37% / 13.47% |
WinMYGN / S&P 24.36% / -1.41% |
| 2022-Q20/3 |
LoseMYGN / S&P -27.90% / -16.10% |
LoseMYGN / S&P 1.49% / 13.71% |
LoseMYGN / S&P -81.25% / 11.04% |
| 2022-Q11/3 |
LoseMYGN / S&P -8.70% / -4.60% |
WinMYGN / S&P 20.52% / 15.97% |
LoseMYGN / S&P -93.91% / 42.23% |
| 2021-Q41/3 |
LoseMYGN / S&P -14.52% / 11.03% |
WinMYGN / S&P 23.96% / 15.00% |
LoseMYGN / S&P -87.33% / 96.40% |
| 2021-Q32/3 |
WinMYGN / S&P 5.59% / 0.58% |
WinMYGN / S&P 14.56% / 10.77% |
LoseMYGN / S&P -70.11% / 69.42% |
| 2021-Q20/3 |
LoseMYGN / S&P 0.43% / 8.55% |
LoseMYGN / S&P 3.73% / 6.58% |
LoseMYGN / S&P -52.42% / 51.81% |
| 2021-Q11/3 |
WinMYGN / S&P 54.02% / 6.17% |
LoseMYGN / S&P -25.58% / -1.06% |
LoseMYGN / S&P -1.50% / 7.39% |
| 2020-Q42/3 |
WinMYGN / S&P 51.61% / 12.15% |
LoseMYGN / S&P -31.51% / -3.72% |
WinMYGN / S&P 733.33% / -33.42% |
| 2020-Q32/3 |
WinMYGN / S&P 14.99% / 8.93% |
LoseMYGN / S&P -28.45% / -2.04% |
WinMYGN / S&P 1086.36% / -27.10% |
| 2020-Q20/3 |
LoseMYGN / S&P -20.75% / 20.54% |
LoseMYGN / S&P -24.97% / -0.46% |
LoseMYGN / S&P -5480.00% / -27.11% |
| 2020-Q10/3 |
LoseMYGN / S&P -47.45% / -19.60% |
LoseMYGN / S&P -8.29% / 3.47% |
LoseMYGN / S&P -766.67% / -14.75% |
| 2019-Q40/3 |
LoseMYGN / S&P -4.89% / 9.07% |
LoseMYGN / S&P 2.17% / 5.36% |
LoseMYGN / S&P -205.88% / 2.99% |
| 2019-Q32/3 |
WinMYGN / S&P 3.06% / 1.70% |
WinMYGN / S&P 8.85% / 5.02% |
LoseMYGN / S&P -129.73% / 0.21% |
| 2019-Q21/3 |
LoseMYGN / S&P -16.33% / 4.30% |
WinMYGN / S&P 14.44% / 6.64% |
LoseMYGN / S&P -97.33% / 8.65% |
| 2019-Q12/3 |
WinMYGN / S&P 14.21% / 13.65% |
WinMYGN / S&P 17.24% / 8.12% |
LoseMYGN / S&P -83.33% / 14.29% |
| 2018-Q41/3 |
LoseMYGN / S&P -36.80% / -13.52% |
WinMYGN / S&P 10.35% / 9.05% |
LoseMYGN / S&P -80.35% / 18.23% |
| 2018-Q31/3 |
WinMYGN / S&P 23.09% / 7.71% |
LoseMYGN / S&P 5.10% / 10.21% |
LoseMYGN / S&P -46.76% / 19.06% |
| 2018-Q22/3 |
WinMYGN / S&P 26.46% / 3.43% |
LoseMYGN / S&P 2.06% / 9.03% |
WinMYGN / S&P 648.00% / 14.46% |
| 2018-Q11/3 |
LoseMYGN / S&P -13.97% / -0.76% |
LoseMYGN / S&P -4.89% / 7.68% |
WinMYGN / S&P 429.41% / 12.46% |
| 2017-Q41/3 |
LoseMYGN / S&P -5.06% / 6.64% |
LoseMYGN / S&P -2.20% / 7.03% |
WinMYGN / S&P 130.67% / 13.82% |
| 2017-Q32/3 |
WinMYGN / S&P 40.02% / 4.48% |
LoseMYGN / S&P -0.60% / 5.68% |
WinMYGN / S&P 19.83% / 17.57% |
| 2017-Q21/3 |
WinMYGN / S&P 34.58% / 3.09% |
LoseMYGN / S&P -1.58% / 4.83% |
LoseMYGN / S&P -84.38% / 17.74% |
| 2017-Q11/3 |
WinMYGN / S&P 15.18% / 6.07% |
LoseMYGN / S&P -1.67% / 3.67% |
LoseMYGN / S&P -79.27% / 13.32% |
| 2016-Q40/3 |
LoseMYGN / S&P -19.00% / 3.82% |
LoseMYGN / S&P -1.14% / 2.09% |
LoseMYGN / S&P -48.63% / 7.05% |
| 2016-Q30/3 |
LoseMYGN / S&P -32.75% / 3.85% |
LoseMYGN / S&P -0.38% / 0.20% |
LoseMYGN / S&P -9.37% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | MYGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.08% | 20.78% |
| Annualized return | -50.08% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | MYGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.33% | 83.14% |
| Annualized return | -38.67% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | MYGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -84.44% | 319.30% |
| Annualized return | -16.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |